FeesSafety
Pluang+

Darolutamide with ADT and radiation cuts prostate cancer spread or death risk by 58% in high-risk patients

Company Fundamentals
24 Oct 2026
Globe News Wire
View Source
Bullish
Darolutamide with ADT and radiation cuts prostate cancer spread or death risk by 58% in high-risk patients

A phase 3 trial shows that darolutamide combined with androgen deprivation therapy (ADT) and radiation reduces the risk of prostate cancer spread or death by 58% compared to placebo in patients at high risk of recurrence. After four years, 95% of patients on darolutamide were metastasis-free versus 88% on placebo. Secondary outcomes also favored darolutamide, with manageable safety profiles similar to placebo. The results, presented at the 2026 ESMO Congress, support darolutamide's potential to improve long-term disease control in early-stage high-risk prostate cancer, though it is not yet approved for this use.

Darolutamide combined with ADT and radiation reduced the risk of prostate cancer spread or death by 58%. For readers following the health sector, here is Pluang's market snapshot as of Oct 24, 2026 13:41 WIB: out of 150 priced US health stocks, 44 rose and 105 fell. Notable movers include HIMS at USD 27.71 with a 4.87% decline and a typical hold time of 22 days, AMLX at USD 27.20 down 4.80%, and TVTX at USD 50.05 down 4.54% with a 9-day hold time.

More News

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
2 hours ago
Darolutamide with ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer patients.

Darolutamide with ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer patients.

Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...

Company Fundamentals
Bullish
4 hours ago
Solana outperforms XRP with higher transactions and stablecoin use, boosting optimism for its price.

Solana outperforms XRP with higher transactions and stablecoin use, boosting optimism for its price.

Motley Fool's recent analysis highlights Solana's stronger network activity compared to XRP, with Solana processing 3.18 billion transactions in September 2026 versus XRP's 222.4 million in Q2 2026. Solana also supports a larger stablecoin supply of ...

Market News
Bullish
4 hours ago
XRP Ledger holds $641M in real-world assets, far behind Ethereum's $16B total

XRP Ledger holds $641M in real-world assets, far behind Ethereum's $16B total

As of October 24, the XRP Ledger had $641.17 million in distributed real-world assets, significantly less than Ethereum's $16.05 billion and other blockchains like BNB Chain, Solana, and Stellar. The XRP Ledger tracked 451 assets excluding stablecoin...

Protocol Fundamentals
Neutral
4 hours ago
South Korea's KOSPI falls 2.8% amid global market de-risking and bond market vulnerabilities.

South Korea's KOSPI falls 2.8% amid global market de-risking and bond market vulnerabilities.

South Korea's tech-heavy KOSPI index dropped 2.8% with major stocks Samsung and SK Hynix falling sharply. This decline reflects a broader global trend of de-risking and deleveraging, especially in highly leveraged European and U.S. bond markets, whic...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App